Early Phase II Clinical Study of SS320A.
|
Accession number;02A0208993
|
| Title;Early Phase II Clinical Study of SS320A. |
| Author;
NAGAOKA SHIGERU
(Japan Res. Inst. Sputum)
TAKISHIMA TAMOTSU
(Tohokudai I Byoin Daiichinaika)
NAGANO HITOSHI
(National Sanatorium Minami Fukuoka Hospital)
MIURA KAZUKI
(Akitadai I Byoin Daininaika)
TAKAHASHI KEIJI
(Yamagatadai I Byoin Daiichinaika)
NAKAMURA SEIICHI
(Tokyotohiroobyoin Kokyukika)
NOGUCHI EISEI
(Showadai Fujigaokabyoin Kokyukinaika)
ODAGIRI TOJI
(Showa Univ., Toyosu Hospital)
DAIMARU NAOKO
(Kokuritsuryoyoshominamifukuokabyoin Naika)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.18;NO.1;PAGE.67-80(2002)
|
| Figure&Table&Reference;FIG.1, TBL.18, REF.25 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;To 41 patients with chronic respiratory diseases (chronic bronchitis, bronchiectasis, pulmonary emphysema, latent pulmonary tuberculosis, diffuse panbronchiolitis, etc.) complaining of the difficulty in expectoration of sputum (under relatively stable disease conditions), SS320A was given at a daily dose of 1.8g (divided into 3) for 2 weeks, and the efficacy and safety as an mucoactive agent were investigated. In the final global improvement rating (evaluated with an index, the subjective symptoms related to the difficulty in expectoration of sputum), the rate of cases assessed as "moderately improved" or more was 64% (23/36 cases), that as "safe" was 98% (40/41 cases) in the safety rating, and that as "useful" or more was 64% (23/36 cases) in the usefulness rating. An adverse reaction was observed a mild heart burn in 1 case (2.4%). An abnormal change in clinical laboratory findings was observed a mild elevation of hematocrit value in 1 case (2.8%). From the results of present study, SS320A showed high efficacy and safety in treatment of chronic respiratory diseases and it was suggested to be a highly useful mucoactive agent. (author abst.) |
|
|
|
Related Articles;
|
|
